To assess ease of use, acceptability and preference of Norditropin NordiFlex® in subjects on prescribed growth hormone therapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-017387-16

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to investigate how easy/difficult patients/parents assess growth hormone injection using Norditropin NordiFlex® by quantifying the proportion of patients that find growth hormone injection using Norditropin NordiFlex® easy or very easy as assessed by patient/parent questionnaire at the end of study.


Critère d'inclusion

  • children aged 6 years or more receiving growth hormone therapy for the following approved indications (according to Norditropine SPC) -GHD -Turner Syndrome -small for gestational age -chronic renal insufficiency

Liens